Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial
暂无分享,去创建一个
H. Goldschmidt | C. Bokemeyer | A. Benner | D. Tichy | K. Weisel | A. Asemissen | R. Lutz | Aneta Schieferdecker | M. Zago | B. Besemer | C. Mann